Together with our previous findings of a requirement for Kmt2a, our data suggest that MN1 drives a leukemic program mediated by the Menin/Kmt2a complex, and that disrupting this complex represents a new therapeutic strategy in MN1-driven AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.